SFA Therapeutics
Regulating the immune system to block cancer & autoimmune diseases
What is the core problem you are solving? Why is this a big problem? What made you decide to work on it?
A completely new approach to treating autoimmune disease, by treating the underlying disease instead of suppressing the immune system.
What is your long-term vision? If you truly succeed, what will be different about the world?
Functional cures for autoimmune diseases
What is your company going to make? Please describe your product and what it does or will do.
SFA Therapeutics, Inc is a biotech with a novel immunomodulatory platform that is focused on the intersection of NF-kB and Ras in the treatment of chronic inflammatory diseases and oncogenesis (the onset of cancer), respectively.
Our vision is to change the practice of Medicine by treating chronic inflammatory conditions that result in cancer, such as hepatitis, which progresses to liver cancer, and pancreatitis, which progresses to pancreatic cancer, by blocking the primary inflammatory pathways with our discoveries..
SFA is developing small molecule drugs originally derived from human GI bacterial metabolites, which have been shown to modulate the immune system through a complex cascade that affects several important molecular pathways, ultimately downregulating NF-kB and RAS, which control involved in inflammation and carcinogenesis. This platform has led to the development of six drugs to treat immuno-inflammatory diseases, using psoriasis as a proof-of concept for autoimmune diseases and chronic liver diseases that are caused by inflammation, including Hepatitis B virus-mediated chronic liver disease, NASH and Hepatocellular Carcinoma (HCC), the most common form of liver cancer. SFA’s two most advanced assets are SFA001 and SFA002, for liver disease and autoimmune diseases, respectively. SFA002 has an approved IND and is ready to enter into clinical trials in patients.
Our plan is to develop these drugs through phase 2 and create phase 3-ready assets, to license to pharma and biotech partners, in exchange for license fees, royalties and milestone payments.